Barclays
COGT icon

Barclays’s Cogent Biosciences COGT Stock Holding History

Barclays’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,000
Closed -$567K – 5520
2025
Q2 		$567K Buy
+79,000
New +$438K ﹤0.01% 3693

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Barclays's COGT Position: Q2 2026 in Review

Barclays increased its Cogent Biosciences (COGT) stake by 53% in Q2 2026, buying an estimated $584K and bringing the position to 47,963 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2387.

Barclays first reported a position in COGT in Q2 2018 and has held it in 25 quarters since. The position peaked at $11.4M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Barclays held 47,963 shares of Cogent Biosciences worth $1.86M as of Q2 2026.
  • Barclays bought 16,702 Cogent Biosciences shares in Q2 2026, an estimated $584K.
  • Cogent Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2387 holding.
  • Barclays first reported a position in Cogent Biosciences in Q2 2018 and has held it in 25 quarters since.
  • Barclays's Cogent Biosciences position peaked at $11.4M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.